-
Nov 20, 2024 | 
healio.com | Erik Swain |Richard Smith |Mikhail Kosiborod |Anu Lala
Potassium binder helps optimize spironolactone use in patients with HF, hyperkalemia risk• A potassium binder enabled more patients with heart failure to stay on spironolactone. • There was a signal of increased risk for HF hospitalization with the potassium binder. CHICAGO — A potassium binder helped patients with HF who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk, researchers reported.
-
Nov 19, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mikhail Kosiborod |Julia Grapsa |Milind Y. Desai
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone. Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).
-
Nov 19, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mikhail Kosiborod |Julia Grapsa |Milind Y. Desai
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone. Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).
-
Nov 18, 2024 | 
radcliffecvrm.com | Harriette Van Spall |Harold Bays |Mikhail Kosiborod
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile. Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD). The FLOW trial (NCT03819153) is designed to assess the effect of semaglutide as compared to placebo in patients with chronic kidney disease and type 2 diabetes.
-
Nov 4, 2024 | 
onlinelibrary.wiley.com | Sean Wharton |Mikhail Kosiborod |Elke Platz |Martina Brueckmann
What is already known? Antiobesity medications (AOMs) in conjunction with lifestyle changes are recommended for the treatment of obesity, but only a few AOMs are available to combat this highly prevalent and heterogenous disease. Survodutide is a dual glucagon and glucagon-like peptide-1 (GLP-1) receptor agonist under investigation for the treatment of obesity in people with BMI ≥ 30 kg/m2 or ≥27 kg/m2 with at least one obesity-related complication. What do these studies add?
-
Nov 1, 2024 | 
jacc.org | Mikhail Kosiborod |David Cherney |Akshay S. Desai |Jeffrey M. Testani
AbstractBackgroundMineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused in clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for the suboptimal use of MRA. ObjectivesWe evaluated the effects of sodium zirconium cyclosilicate (SZC) in optimizing use of spironolactone among participants with HFrEF and hyperkalemia.
-
Oct 15, 2024 | 
radcliffecvrm.com | Mikhail Kosiborod |Maria Serova |Maria Chashkina |John McMurray
Video Published: Views: 44 Likes: 0 Average (ratings) HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline. Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population? 3.
-
Oct 8, 2024 | 
healio.com | Scott Buzby |Erik Swain |Mikhail Kosiborod
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Wegovy improved exercise function among patients with obesity-related heart failure with preserved ejection fraction. The greatest improvements were observed in those with the most weight lost at 52 weeks.
-
Sep 4, 2024 | 
healio.com | Michael Monostra |Richard Smith |Mikhail Kosiborod
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Semaglutide lowered the risk for worsening heart failure or CV death by 31% compared with placebo. The risk for a worsening heart failure event was 41% lower in the semaglutide group vs. placebo.
-
Jul 9, 2024 | 
onlinelibrary.wiley.com | Joao Ferreira |Jonathan Blatchford |John R. Teerlink |Mikhail Kosiborod
Supporting Information Filename Description ejhf369-sup-0001-FigureS1.docxWord 2007 document , 365.2 KB Appendix S1. Supporting Information. References 1, , , , , , et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 2022; 28: 568–574. https://doi.org/10.1038/s41591-021-01659-1 2, , , , , , et al. Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial.
